<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IMATINIB" rxcui="282388">
<ATC code="L01XE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not reommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, strict clinical monitorinig and frequent testing of the INR</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IMATINIB" rxcui="282388">
<ATC code="L01XE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the thyroid hormones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
